StockNow
Calendar
Log in
Global Markets

AstraZeneca (AZN LN) biopharma head says that they are on track to hit 2030 revenue target

StockNow breaking-news AI analysis

The October 9 headline says AstraZeneca’s biopharma head sees the 2030 target as on track, but the record lacks details; July reporting identified the target as $80 billion.

1 stocks
AZNAstraZeneca PLC$160.08Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Geopolitics

A US military source told Al-Hadath that "US forces received orders to mobilise last Sunday"; "We have replaced thousands of missiles and sent our forces the ammunition they need"

Geopolitics

"[Yemen] Government forces complete control over Bab al-Mandab after clearing it", Al Hadath reports citing sources

Geopolitics

IRGC Navy political affairs officer says vessels violating restrictions in the Strait of Hormuz are punished every night, via Arabic TV